Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Calix drops despite earnings beat (SeekingAlpha) +++ CALIX Aktie -4,68%

BOSTON SCIENTIFIC Aktie

 >Aktienkurs 
55.51 EUR    +9.4%    (TradegateBSX)
Ask: 55.6 EUR / 540 Stück
Bid: 55.42 EUR / 550 Stück
Tagesumsatz: 5250 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: -6,2%
1 Monat: -15,7%
3 Monate: -35,4%
6 Monate: -40,8%
1 Jahr: -39,1%
laufendes Jahr: -37,5%
>BOSTON SCIENTIFIC Aktie
Name:  BOSTON SCIENTIFIC DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US1011371077 / 884113
Symbol/ Ticker:  BSX (Frankfurt) / BSX (NYSE)
Kürzel:  FRA:BSX, ETR:BSX, BSX:GR, NYSE:BSX
Index:  S&P500
Webseite:  http://www.bostonscientif..
Profil:  Boston Scientific Corporation develops, manufactures, and markets a broad portfolio of medical devices designed for minimally invasive procedures worldwide. The company specializes in innovative technologies that address critical health needs across ..
>Volltext..
Marktkapitalisierung:  77217.55 Mio. EUR
Unternehmenswert:  85907.51 Mio. EUR
Umsatz:  17101.84 Mio. EUR
EBITDA:  4633.47 Mio. EUR
Nettogewinn:  2468.8 Mio. EUR
Gewinn je Aktie:  1.67 EUR
Schulden:  10198.92 Mio. EUR
Liquide Mittel:  1742.13 Mio. EUR
Operativer Cashflow:  3862.5 Mio. EUR
Bargeldquote:  0.38
Umsatzwachstum:  5.66%
Gewinnwachstum:  37.85%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  BOSTON SCIENTIFIC
Letzte Datenerhebung:  22.04.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 1486.18 Mio. St.
Frei handelbar: 99.63%
Rückkaufquote: -0.31%
Mitarbeiter: 59000
Umsatz/Mitarb.: 0.29 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 55.89%
Bewertung:
KGV: 31.8
KGV lG: 17.93
KUV: 4.73
KBV: 3.77
PEG-Ratio: 0.59
EV/EBITDA: 18.54
Rentabilität:
Bruttomarge: 65.04%
Gewinnmarge: 14.44%
Operative Marge: 20.28%
Managementeffizenz:
Gesamtkaprendite: 6.98%
Eigenkaprendite: 12.6%
 >Anleihen 
>Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege, Nierenerkrankungen & -behandlung, Onkologie/ Krebs- Behandlung, Herz-Kreislauf- Behandlung/ Kardiologie
 
22.04.26 - 16:00
 GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday (Benzinga)
 
U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares rose 14.1% after beating estimates and raising sales guidance. Importance Rank:  1 read more...
22.04.26 - 15:24
 Boston Scientific übertrifft Erwartungen in Q1, senkt aber Jahresprognose – Aktie legt zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
22.04.26 - 15:15
 Boston Scientific (BSX) Q1 Earnings Match Estimates (Zacks)
 
Boston Scientific (BSX) delivered earnings and revenue surprises of +0.59% and +0.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...
22.04.26 - 15:03
 BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Electrophysiology Procedure Growth: Levi & Korsinsky (PR Newswire)
 
Key Dates and Disclosure Events Shareholders Need to Know NEW YORK, April 22, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP encourages investors who suffered losses in Boston Scientific Corporation (NYSE: BSX) to contact the firm. Those who purchased BSX securities between July 23, 2025, and......
22.04.26 - 14:06
 Boston Scientific cuts 2026 profit forecast, trims revenue growth view (Reuters EN)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
22.04.26 - 13:24
 Boston Scientific Lowers FY26 Guidance (AFX)
 
WASHINGTON (dpa-AFX) - Boston Scientific (BSX) said it now estimates net sales growth for the full year 2026 to be approximately 7.0 to 8.5 percent on a reported basis and 6.5 to 8.0 percent on an......
22.04.26 - 13:18
 Boston Scientific Net Grows Sharply (WSJ EN)
 
Boston Scientific said its first-quarter net income roughly doubled as demand continued to grow worldwide for its stents, catheters and other cardiology devices....
22.04.26 - 13:01
 Boston Scientific Corp Announces Climb In Q1 Bottom Line (AFX)
 
WASHINGTON (dpa-AFX) - Boston Scientific Corp (BSX) reported a profit for its first quarter that Increases, from last yearThe company's bottom line came in at $1.34 billion, or $0.90 per share. Th......
22.04.26 - 13:00
 Boston Scientific cuts full-year outlook despite Q1 beat (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.04.26 - 12:36
 Boston Scientific Non-GAAP EPS of $0.80 beats by $0.01, revenue of $5.2B beats by $30M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.04.26 - 12:31
 Boston Scientific announces results for first quarter 2026 (PR Newswire)
 
MARLBOROUGH, Mass., April 22, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational1 and organic2 basis, all compared to the prior......
21.04.26 - 17:24
 Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love (24/7 Wall St.)
 
Boston Scientific (NYSE: BSX) trades around $61, with analyst price targets ranging from $69 (conservative) to $124 (optimistic), implying substantial upside. Abbott Laboratories (NYSE: ABT) trades near $95 against an optimistic target of $143. Both trade at or near 52-week lows while Wall Street analysts maintain bullish ratings. Boston Scientific makes cardiovascular devices, endoscopy tools, ... Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love...
21.04.26 - 15:54
 BSX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and......
21.04.26 - 00:00
 BSX Deadline: BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, April 20, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), of the important May 4, 2026 lead......
19.04.26 - 16:45
 Boston Scientific: Warum der Kurssturz nach der Penumbra-Übernahme eine Einstiegschance ist (Tim Schaefer)
 
Die Wall Street ist extrem kurzsichtig. Sobald eine kleine Wolke am Horizont auftaucht, werfen nervöse Anleger ihre Papiere… Der Beitrag Boston Scientific: Warum der Kurssturz nach der Penumbra-Übernahme eine Einstiegschance ist erschien zuerst auf Tim Schäfer Media....
17.04.26 - 21:33
 Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
 
BENSALEM, Pa., April 17, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). IF......
17.04.26 - 21:15
 Will Robust Cardiovascular Performance Fuel BSX′s Q1 Earnings? (Zacks)
 
Boston Scientific heads into Q1 earnings with strong Cardiovascular momentum and steady MedSurg growth, as estimates point to solid revenue and earnings gains....
17.04.26 - 14:51
 BSX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and......
16.04.26 - 17:06
 INVESTOR DEADLINE: Boston Scientific Corporation (BSX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit (PR Newswire)
 
SAN DIEGO, April 16, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), have until Monday, May 4,......
16.04.26 - 16:03
 INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines - BSX (PR Newswire)
 
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es dauert zehn Jahre, einen Baum, aber hundert Jahre, einen Menschen großzuziehen. - Sprichwort China
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!